Vivos Therapeutics to Participate at the Q1 Virtual Investor Summit
11 mars 2021 07h55 HE
|
Vivos Therapeutics Inc.
Vivos management to present at 1:30 pm Eastern Time on March 23, 2021 HIGHLANDS RANCH, Colo., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Vivos Therapeutics, Inc. (“the Company”)...
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
08 févr. 2021 21h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the...
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)
17 nov. 2020 01h00 HE
|
Nyxoah
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA) DREAM is a pivotal, Investigational Device Exemption (IDE) study,...
InvestorBrandNetwork (IBN) Coverage Initiated for Vivos Therapeutics Inc.
11 juin 2020 08h30 HE
|
Vivos Therapeutics Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Vivos Therapeutics Inc., a company focused on addressing the root causes of mild to moderate sleep apnea, today announces it has...
Novel Oral Device a Breath of Fresh Air for Canadian Sleep Apnea Sufferers
03 mars 2020 08h41 HE
|
Oventus Medical Ltd
TORONTO, March 03, 2020 (GLOBE NEWSWIRE) -- Canadians living with obstructive sleep apnea (OSA) who are frustrated with cumbersome and uncomfortable CPAP machines can breathe easier thanks to an...
Nyxoah raises €25 million in private funding round
13 févr. 2020 07h58 HE
|
Nyxoah
Nyxoah raises €25 million in private funding round Mont-Saint-Guibert, Belgium – 12 February 2020, Nyxoah S.A., a healthtech company developing neuromodulation-based therapeutic solutions for sleep...
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
03 févr. 2020 09h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
Sleep Tech Devices Market value to cross $27 billion by 2025: Global Market Insights, Inc.
05 nov. 2019 05h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Global Sleep Tech Devices Market is projected to surpass USD 27 billion by 2025, according to a new research report by Global Market...
RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia
19 févr. 2019 08h50 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
10 sept. 2018 15h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...